#Sweden #Stockholm #Leqembi #BioArctic #Nasdaq Stockholm

BioArctic AB Share Update

On February 27, 2026, BioArctic AB (publ), traded on Nasdaq Stockholm under the ticker BIOA B, disclosed a significant development regarding its share structure. The company has issued 78,000 Class B shares during February, specifically to fulfill the allocations from the 2019/2028 stock option program established at the Annual General Meeting in May 2019. The issuance of these shares represents an exercise of stock options from the same series.

This recent transaction has brought the total number of shares issued by BioArctic to 88,719,485. Out of these, 74,319,489 are listed Class B shares, while 14,399,996 remain unlisted Class A shares. It's important to note the distinct voting rights associated with these classes: each A share carries ten votes, while B shares provide holders with one vote each. Consequently, the total voting rights within the company now stand at 218,319,449 votes.

The update was mandated by the EU Market Abuse Regulation, ensuring transparency and compliance with regulatory standards. The public disclosure was facilitated through the company's contact person on the specified date, indicating the ongoing commitment of BioArctic to maintain clear and open communication with its investors and stakeholders.

In addition to this update, it is essential to highlight BioArctic's pivotal role in the biopharmaceutical landscape. The company specializes in developing innovative treatments, particularly for neurodegenerative diseases. They are renowned for the creation of Leqembi® (lecanemab), which is recognized as the world's first drug capable of slowing the progression of and alleviating cognitive impairment in early Alzheimer's disease. Developed in partnership with Eisai, BioArctic is not only dedicated to advancing this landmark treatment but also houses a diverse research portfolio focused on conditions like Parkinson's disease and ALS.

BioArctic has also pioneered the BrainTransporter™ technology, which aims to effectively transport antibodies across the blood-brain barrier, enhancing the efficacy of their therapies. This innovative approach is a testament to the company's commitment to ensuring that their treatments reach the intended targets within the brain, consequently improving patient outcomes.

As BioArctic continues to expand its footprint in the global biopharma industry, the recent share issuance highlights both its growth trajectory and its dedication to engaging with shareholders. The market’s reaction to such updates is always of interest, and investors are encouraged to keep a close watch on the progress of BioArctic as they navigate the complexities of drug development and regulatory approval processes.

For more information about BioArctic's offerings, research focus, and latest updates, interested parties can visit their official website at BioArctic's website.

Inquiries regarding this announcement can be directed to:

• - Oskar Bosson, VP of Communications and Investor Relations (Email: [email protected], Tel: +46 704 10 71 80)
• - Anders Martin-Löf, CFO (Email: [email protected], Telephone: +46 70-683 79 77).

With advancements like these, BioArctic remains a key player in the fight against neurodegenerative diseases, with the potential to transform patient experiences and outcomes in the years to come.